Michigan Weight Navigation Program (MiWeigh) to help adults with obesity lose weight

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults with BMI ≥30 and one or more weight-related conditions are randomized to the MiWeigh intervention or to enhanced usual care. The MiWeigh arm receives a combination of virtual provider visits, regular messaging through the electronic health record portal, and weekly weight reporting by text, while both arms complete questionnaires and periodic blood draws. The study tracks weight change over time and includes process measures to determine which program components work and why. If effective, the protocol is intended to inform how other health systems could implement similar weight-navigation services.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Body Mass index (BMI) 30 kilogram per square meter or higher
* Diagnosed with one or more of the following weight-related conditions:

  * Type 2 Diabetes
  * Prediabetes Mellitus
  * Hyperlipidemia (HLP)
  * Hypertension (HTN)
  * Polycystic Ovary Syndrome (PCOS)
  * Obstructive Sleep Apnea (OSA) and/or
  * Metabolic dysfunction-associated steatotic liver disease (MASLD)
* Speaks English
* Interest in losing weight
* Willingness to complete assessments per study protocol
* Willing and able to use the Electronic health records patient portal to respond to messages
* Willing to report weight weekly by text if randomized to intervention arm
* Able to see provider virtually at certain days/times up to four times in a year

Exclusion Criteria:

* ≥ 5% weight loss within the prior 12 months
* Has had a Weight Navigation Program visit in past
* Pregnant, planning a pregnancy, or breastfeeding in the next year
* Ongoing participation in another weight-loss program
* Taking an anti-obesity medication
* Ever diagnosed with Type 1 Diabetes Mellitus (per protocol)
* Dementia
* Serious uncontrolled mental health conditions as indicated (per protocol)
* Chronic kidney disease, Stage 4 or higher
* Alcohol dependence and opioid dependence (per protocol)
* History of anorexia or bulimia
* Bariatric/ gastric bypass surgery, gastric sleeve surgery, or gastric balloon procedure in last year
* Currently enrolled in an interventional research study that is examining how a diet, program, or drug might: promote physical exercise, healthy eating habits, or weight loss; lower blood pressure; or lower blood sugar
* Not planning to live in local area over the next year
* Intensive cancer treatment such as bone marrow transplant, chemotherapy, radiation, or cancer related surgery (not including hormonal chemotherapy like Tamoxifen) in last six months or next 12 months
* Other serious health issues or personal concerns that could prevent participant from completing study

Where it's running

• University of Michigan
  Ann Arbor, Michigan, United States Recruiting

Study contacts

• Principal investigator: Dina Griauzde, MD, MSc — University of Michigan
• Study coordinator: Shelley Stoll
• Email: scstoll@med.umich.edu
• Phone: 734-232-0697

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.